Uremic Pruritus Clinical Trial
Background.
Uremic pruritus is still a common phenomenon in patients with end-stage renal failure. It is
regarded as one of the most bothersome symptoms in patients on chronic dialysis.
The pathogenesis of uremic itch remains unclear. Several theories have been proposed like
dryness of the skin, imbalance in divalent ions, peripheral neuropathy and others.
Many treatment modalities have been tried to reduce uremic pruritus, however , the majority
of them produced only temporary improvement. Therefore , every new therapeutic option for
uremic pruritus is desirable.
This study will undertaken to evaluate the efficacy of a cream which included olive oil and
omega-3 fatty acids.
Olive Omega-3 is an efficient product that soothes itchiness of cracked and very dry skin.
The product is unique and based on patented technology developed by the Technion Research
and Development Foundation in Haifa.
Olive Omega-3 is an ointment composed of all natural ingredients. The main active
ingredients are extra virgin olive oil , fish oil and vitamin C. The oils provides the skin
with fatty acids that are vital for its proper functioning and help in the skin recovery.
Sugar cane extract improves the skin's flexibility by removing dead cells and enhancing
water retention in the upper layer of the skin.
When applied on clean skin , the product is quickly absorbed , producing a sensation of
relief within a short time period. Treatment can be repeated as often as required with no
limitations and its use is not contraindicative of any other medical treatment.
Patients and Methods.
About 20 patients on chronic hemodialysis suffering from uremic pruritus will be include in
the study.
All patients will undergo dermatologic examination. All patients will be score by intensity
of itching according to 3-point scale , as follows:
1. - patches of fine , powdery scales
2. - moderate scaling with beginning cracks
3. - intense scaling , moderate cracks The patients all applied Olive Omega-3 ointment for
50% of body and Vaseline ointment for the second one. The treatment will repeated twice
daily for two weeks.
At the end of 2 weeks application global tolerance will evaluate using the following 3-point
scale:
1. very good
2. good
3. poor
At the same time global agreement of the patients will evaluate according to the following
scale :
1. - very satisfactory
2. - satisfactory 3- poorly satisfactory.
Statistical analysis will be performed by use of Wilcoxon test .
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04728984 -
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
|
Phase 3 | |
| Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
| Terminated |
NCT01660243 -
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
|
Phase 2 | |
| Completed |
NCT06159686 -
The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05525234 -
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
|
Phase 4 | |
| Completed |
NCT03002233 -
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
|
Phase 1 | |
| Completed |
NCT03998163 -
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
| Active, not recruiting |
NCT05885737 -
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
| Recruiting |
NCT04393675 -
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03576235 -
Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients
|
N/A | |
| Completed |
NCT05575193 -
Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis
|
N/A | |
| Completed |
NCT02858726 -
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 2/Phase 3 | |
| Completed |
NCT02143648 -
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
| Completed |
NCT00494975 -
The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
|
N/A | |
| Completed |
NCT03758079 -
Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus
|
Phase 4 | |
| Completed |
NCT02229929 -
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
|
Phase 2 | |
| Completed |
NCT04639674 -
AST-120 in Hemodialysis Patients With Uremic Pruritus
|
Phase 4 | |
| Completed |
NCT03636269 -
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
| Completed |
NCT04711603 -
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
|
Phase 3 | |
| Completed |
NCT02696499 -
Treatment of Uremic Pruritus With PA101B
|
Phase 2 |